PSPatamawadee Silalai

Patamawadee Silalai

*This is an algorithmically generated author record based on publicly available information.

Patamawadee Silalai has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Zn(OAc)2·2H2O-Catalyzed Sulfurization Reaction of Alkenes: A Selective and Direct One-Pot Synthesis of β-Hydroxysulfides and Thioetherpyridines

    by Patamawadee Silalai, Suwichada Jaipea, Rungnapha Saeeng

    β-Hydroxysulfides are valuable intermediates in pharmaceutical and synthetic chemistry. In this study, we present an efficient method for synthesizing β-hydroxysulfides via the radical pathway for sulfurization reaction of alkenes using Zn­(OAc)2·2H2O as an inexpensive and environmentally friendly catalyst, yielding products in good to excellent yields. Notably, vinylpyridine serves as an effective substrate, leading to the formation of unique thioetherpyridine products in high yields. These products are versatile and can undergo additional transformations, broadening their synthetic utility. The advantages of this method include a broad substrate scope, mild conditions, and high compatibility with various functional groups.


  • Open Access

    Design and Synthesis of Mycophenolic Acid Analogues for Osteosarcoma Cancer Treatment

    by Patamawadee Silalai, Pimpisa Teeyakasem, Dumnoensun Pruksakorn, Rungnapha Saeeng

    Mycophenolic acid (MPA), a natural compound, was modified to new MPA analogues via the classical method of silylation and esterification. Their cytotoxicity was evaluated in vitro on four osteosarcoma cancer cell lines (MNNG/HOS, U2OS, 143B, and SaOS-2) and human normal cells (hFOB 1.19). The most potent silicon-containing compound 2d (R1 = TPS, R2 = H) exhibited good cytotoxic activity against all osteosarcoma cancer cell lines with IC50 values ranging from 0.64 to 2.27 μM and showing low cytotoxicity against normal cells. Further investigations revealed that compound 2d (R1 = TPS, R2 = H) displayed significant inhibition of IMPDH2 with K i app 1.8 μM. Furthermore, molecular modeling studies were performed to investigate the binding affinity of 2d (R1 = TPS, R2 = H) which can effectively bind to critical amino acids of three proteins (vascular endothelial growth factor receptor 2; VEGFR-2, cyclin-dependent kinase 2; CDK2, inosine-5'-monophosphate dehydrogenase; IMPDH) involved in cancer therapy. This finding suggests that triphenylsilyl-MPA (TPS-MPA) analogue could serve as a promising starting point for developing new anticancer drugs for osteosarcoma.


  • Genipin Analogue (G300) Inhibits Adipogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells through the Suppression of Adipogenic Promoting Factors

    by Nittaya Boonmuen, Kanoknetr Suksen, Mintra Kaewkittikhun, Laongthip Ruknarong, Patamawadee Silalai, Rungnapha Saeeng, Arthit Chairoungdua, Sunhapas Soodvilai, Duangrat Tantikanlayaporn

    While obesity is a well-known health threatening condition worldwide, effective pharmacological interventions for obesity suppression have been limited due to adverse effects. Therefore, it is important to explore alternative medical treatments for combating obesity. Inhibition of the adipogenesis process and lipid accumulation are critical targets for controlling and treating obesity. Gardenia jasminoides Ellis is a traditional herbal remedy for various ailments. A natural product from its fruit, genipin, has major pharmacological properties; it is anti-inflammatory and antidiabetic. We investigated the effects of a genipin analogue, G300, on adipogenic differentiation in human bone marrow mesenchymal stem cells (hBM-MSCs). G300 suppressed the expression of adipogenic marker genes and adipokines secreted by adipocytes at concentrations of 10 and 20 mu M, which effectively reduced the adipogenic differentiation of hBM-MSCs and lipid accumulation in adipocytes. It also improved adipocyte function by lowering inflammatory cytokine secretion and increasing glucose uptake. For the first time, we show that G300 has the potential to be a novel therapeutic agent for the treatment of obesity and its related disorders.